ASGE Postgraduate Course at ACG 2022: Expanding the Scope of Fundamental and Advanced Endoscopy (On-Demand) | October 2022-Point Counterpoint: Malignant G astric Outlet Obstruction - Duodenal Stenting Is the Time-Tested Therapy

Point Counterpoint: Malignant G astric Outlet Obstruction - Duodenal Stenting Is the Time-Tested Therapy

Video Transcription

Video Summary

In this video, Philip G presents a pre-recorded lecture on the topic of duodenal stenting as a therapy for pancreatic cancer. He discusses the poor prognosis of pancreatic cancer and the development of malignant gastric outlet obstruction, which results in a short median survival time. He explains that duodenal stenting has a long track record with proven efficacy and compares it to other management options such as surgical GJ and venting gastrostomy. He also questions the limited adoption of EUSGJ due to the steep learning curve and limited availability of trained endoscopists. Lastly, he highlights the advancements in robotic gastrointestinal surgery as competition to EUSGJ. In conclusion, he argues that duodenal stent placement is still a reasonable option in 2022, particularly for patients with limited life expectancy, and emphasizes the need for personalized and multidisciplinary management decisions.

Asset Subtitle

Phillip S. Ge, MD

Keywords

duodenal stenting

pancreatic cancer

malignant gastric outlet obstruction

surgical GJ

venting gastrostomy